The estimated Net Worth of Robert W Duggan is at least $719 Milion dollars as of 12 December 2023. Mr. Duggan owns over 17,999 units of Pulse Biosciences Inc stock worth over $633,908,828 and over the last 21 years he sold PLSE stock worth over $84,696,784. In addition, he makes $234,718 as Independent Chairman of the Board at Pulse Biosciences Inc.
Sign up
Mr. Duggan PLSE stock SEC Form 4 insiders trading
Robert has made over 76 trades of the Pulse Biosciences Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 17,999 units of PLSE stock worth $164,691 on 12 December 2023.
The largest trade he's ever made was buying 376,489,880 units of Pulse Biosciences Inc stock on 6 March 2023 worth over $395,314,374. On average, Robert trades about 3,488,004 units every 45 days since 2003. As of 12 December 2023 he still owns at least 36,984,179 units of Pulse Biosciences Inc stock.
You can see the complete history of Mr. Duggan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Duggan biography
Robert W. Duggan serves as Independent Chairman of the Board of the Company. Mr. Duggan has been Chief Executive Officer of Duggan Investments, Inc., a venture capital and public equity investment firm primarily focused on patient-friendly breakthrough solutions to complex diseases of aging. From September 2007 through the acquisition by AbbVie Inc. in May 2015, Mr. Duggan was a member of the board of directors of Pharmacyclics, Inc., a patient-friendly, science-based, employee-driven developer of small-molecule medicines for the treatment of cancers. Mr. Duggan was also the Chairman and Chief Executive Officer of Pharmacyclics from September 2008 to May 2015 as well as its largest investor. From 1990 to 2003, Mr. Duggan was Chairman of the board of directors of Computer Motion, Inc. From 1997 to 2003, Mr. Duggan also served as Chief Executive Officer of Computer Motion. In June 2003, Computer Motion merged with Intuitive Surgical Inc. From 2003 to 2011, Mr. Duggan served on the board of directors of Intuitive Surgical. Since December 2019, Mr. Duggan has served on the board of directors of Summit Therapeutics plc and was appointed its Executive Chairman in February 2020. Mr. Duggan received a U.S. Congressman's Medal of Merit from Ron Paul in 1985 and in 2000 he was named a Knight of the Legion D’Honor by President Jacques Chirac of France. He is a member of the University of California at Santa Barbara Foundation board of trustees.
What is the salary of Robert Duggan?
As the Independent Chairman of the Board of Pulse Biosciences Inc, the total compensation of Robert Duggan at Pulse Biosciences Inc is $234,718. There are 8 executives at Pulse Biosciences Inc getting paid more, with Sandra Gardiner having the highest compensation of $2,097,570.
How old is Robert Duggan?
Robert Duggan is 75, he's been the Independent Chairman of the Board of Pulse Biosciences Inc since 2017. There are no older and 11 younger executives at Pulse Biosciences Inc.
What's Robert Duggan's mailing address?
Robert's mailing address filed with the SEC is 3957 POINT EDEN WAY, , HAYWARD, CA, 94545.
Insiders trading at Pulse Biosciences Inc
Over the last 8 years, insiders at Pulse Biosciences Inc have traded over $0 worth of Pulse Biosciences Inc stock and bought 18,070,761 units worth $194,618,110 . The most active insiders traders include Robert W Duggan, Mahkam Zanganeh oraz Manmeet Singh Soni. On average, Pulse Biosciences Inc executives and independent directors trade stock every 52 days with the average trade being worth of $6,179,107. The most recent stock trade was executed by Burke Thomas Barrett on 20 May 2024, trading 10,000 units of PLSE stock currently worth $85,600.
What does Pulse Biosciences Inc do?
pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and
What does Pulse Biosciences Inc's logo look like?
Complete history of Mr. Duggan stock trades at Intuitive Surgical Inc, Pulse Biosciences Inc oraz Summit Therapeutics Inc
Pulse Biosciences Inc executives and stock owners
Pulse Biosciences Inc executives and other stock owners filed with the SEC include:
-
Sandra Gardiner,
Chief Financial Officer, Executive Vice President - Finance, Treasurer, Secretary -
Darrin Uecker,
President, Chief Executive Officer, Director -
Darrin R. Uecker,
Pres, CEO & Director -
Sandra A. Gardiner,
Exec. VP of Fin. & Admin., CFO, Sec. and Treasurer -
Mitchell Levinson,
Independent Director -
Edward A. Ebbers,
Exec. VP & GM of Dermatology -
Edward Ebbers,
Executive Vice President, General Manager - Dermatology -
Manmeet Soni,
Independent Director -
Robert Duggan,
Independent Chairman of the Board -
Kenneth Clark,
Independent Director -
Mahkam Zanganeh,
Independent Director -
Mitchell E. Levinson,
Chief Strategy Officer & Director -
David Danitz,
Sr. VP of Engineering -
Patty Perla,
VP of HR -
Dr. Holly Hartman Ph.D., J.D.,
VP of Bus. Devel. & Corp. Strategy -
Dr. Richard Nuccitelli Ph.D.,
Chief Science Officer -
Thierry B. Thaure,
Director -
Robert J. Greenberg,
Director -
Robert Levande,
Director -
Brian B Dow,
CFO & SVP Admin. and Finance -
Thomas J M D Fogarty,
Director -
Burke Thomas Barrett,
President and CEO -
Ed Ebbers,
EVP & GM, Dermatology -
Den Broek Richard Van,
Director -
Laureen Debuono,
Director -
Shelley D Spray,
Director -
Kevin Patrick Danahy,
Chief Commercial Officer -
Paul A Laviolette,
Director